Mechanism-Driven Read-Across of Chemical Hepatotoxicants Based on Chemical Structures and Biological Data

Linlin Zhao1, Daniel P Russo1, Wenyi Wang1

  • 1The Rutgers Center for Computational and Integrative Biology, Camden, New Jersey.

Insights

Predicting drug-induced liver injury (hepatotoxicity) is crucial. This study uses in vitro assay data and chemical fragments to identify potential hepatotoxic compounds, improving drug safety assessments.

Area of Science:

  • Toxicology
  • Computational Chemistry
  • Drug Development

Background:

  • Hepatotoxicity significantly hinders drug development, necessitating costly and time-consuming evaluations.
  • Advancements in high-throughput screening provide extensive in vitro toxicity data for risk assessment.
  • A comprehensive database of 4089 compounds with in vivo hepatotoxicity classifications was curated.

Purpose of the Study:

  • To develop a predictive model for hepatotoxicity using in vitro assay data and chemical structure information.
  • To identify specific chemical fragments (Molecular Initiating Events) associated with in vivo hepatotoxicity.
  • To explore potential mechanisms underlying drug-induced liver injury.

Main Methods:

  • Curated and merged in vivo hepatotoxicity data with public resources.
  • Extracted and clustered PubChem assay data based on structural fragments and cellular responses.
  • Validated predictive models using cross-validation and evaluated test set compounds.

Main Results:

  • Selected PubChem assay clusters demonstrated high predictivity for hepatotoxicity.
  • Compounds with specific chemical fragments and active assay responses showed potential for in vivo hepatotoxicity.
  • Identified potential toxicity mechanisms including nuclear receptor signaling alterations and DNA repair inhibition.

Conclusions:

  • A modeling strategy combining chemical fragments and in vitro assay data can predict in vivo hepatotoxicity.
  • This approach aids in early identification of potential drug liabilities.
  • The methodology is applicable to other toxicity endpoints and drug efficacy studies.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
130
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
1.7K
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
728
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems01:19

Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
622
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.8K
Types of Toxins01:36

Types of Toxins

Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
3.1K